fashion -WSS

fashion

author：Wikipedia 2025-09-09 19:32:53 - browse：6761

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： What should King Charles tell the public about his cancer?

knowledge

hotspot

WSS

Robert F. Kennedy is pitching centrism on health, even on abortion

Medical mystery: When a cough is not just a cough

Key House Republican on health care plans exit from Congress

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Biogen Alzheimer’s drug launch off to slow start

Doctors' information doesn't help them choose wisely when sick

Wikipedia

fashion

hotspot

Cancer drug shortages should be causing more outrage

How to increase colonoscopy rates? Looks like an AI can help

In Memoriam: Notable people who died in 2023

How digital tools helped lower hypertension in marginalized patients

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Walensky prepares to leave CDC — and Congress — behind

To avoid data mishandling cases, universities eye AI and other tools

23andMe had bad news about my health. I wish a person had delivered it

To avoid data mishandling cases, universities eye AI and other tools

hotspot

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Change Healthcare can notify patients about the breach, HHS says

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

See how much Covid

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

explore

knowledge

hotspot

knowledge